Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies

Journal of Clinical Psychiatry

Volumn 74, Issue 10, 2013, Pages 957-965

  Kishimoto, Taishiro ^a,b,c,f   Nitta, Masahiro ^e   Borenstein, Michael ^g   Kane, John M ^a,b,c,d   Correll, Christoph U ^a,b,c,d  

^a North Shore Long Island Jewish Health System Division of Psychiatry Research Zucker Hillside Hospital ^*  (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Biostat Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOPENTHIXOL; CLOPENTHIXOL DECANOATE; CLOZAPINE; DECANOIC ACID; ENANTHIC ACID; FLUPENTIXOL; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PALMITIC ACID; PERPHENAZINE; PERPHENAZINE ENANTHATE; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MEDICAL LITERATURE; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; HUMANS; INJECTIONS; MEDICATION ADHERENCE; PATIENT SELECTION; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA;

EID: 84887080795     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13r08440     Document Type: Review

References (43)

1. Lieberman JA, Perkins D, Belger A., et al The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry. 2001;50(11):884-897. (Pubitemid 34023591)
2. van Haren N.E., Hulshoff Pol HE, Schnack HG, et al Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neurop sy chopharmacology. 2007;32(10):2057-2066. (Pubitemid 47417696)
3. Velligan DI, Weiden PJ, Sajatovic M, et al.; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The Expert Consensus Guideline Series: Adherence Problems in Patients With Serious and Persistent Mental Illness. J Clin Psychiatry. 2009;70(suppl 4):1-46, quiz 47-48.
4. Kane J, Kishimoto T, Correll C. Factors contributing to non-adherence in patients with psychotic disorders. World Psychiatry. In press.
5. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry suppl. 2009;195(52):S63-S67.
6. Rosenheck RA, Krystal JH, Lew R, et al.; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851.
7. Schooler NR, Buckley PF, Mintz J, et al PROACTIVE: Initial results of an RCT comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. American College of Neuropsychopharmacology 50th Annual Meeting; December 4-11, 2011; Kona, Hawaii.
8. Kishimoto T, Robenzadeh A, Leucht C., et al Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials [published online ahead of print January 2, 2013]. Schizophr Bull.
9. Haddad PM, Taylor M, Niaz OS First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry suppl. 2009;195(52):S20-S28. 2210.
10. Davis JM, Matalon L, Watanabe M.D., et al Depot antipsychotic drugs: place in therapy. Drugs. 1994;47(5):741-773. (Pubitemid 24151095)
11. Fleischhacker W.W. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry suppl. 2009;195(52):S29-S36.
12. Moher D, Liberati A, Tetzlaff J., et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
14. Egger M, Davey Smith G, Schneider M, et al Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
15. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463. (Pubitemid 30422636)
16. Chang HC, Tang CH, Huang S.T., et al A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. J Psychiatr Res. 2012;46(6):751-756.
17. Rosa F, Schreiner A, Thomas P., et al Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig. 2012;32(4):267-279.
18. Crivera C, DeSouza C, Kozma C.M., et al Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC Psychiatry. 2011;11(1):168.
19. Ren XS, Crivera C, Sikirica M., et al Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the Veterans Health Administration. J Clin Pharm Ther. 2011;36(3):383-389.
20. Peng X, Ascher-Svanum H, Faries D., et al Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2011;3:9-14.
21. Carswell C, Wheeler A, Vanderpyl J., et al Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig. 2010;30(11):777-787.
22. Girardi P, Serafini G, Pompili M., et al Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Phar macopsychiatry. 2010;43(2):66-72.
23. Su K.P., Chang HC, Tsai S.J., et al Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Valu e He alth. 2009;12(SUPPL. 3):S118-S121.
24. Lam A, Chue P, Ligate L., et al p.3.c.068 efficacy outcomes of risperidone long acting injection in patients previously on oral atypicals versus conventional depots. Eur Neuropsychopharmacol. 2009;19:S549-S550.
25. Fuller M, Shermock K, Russo P., et al Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Media Econ. 2009;12(4):317-324.
26. Beauclair L, Lam A, McCormick J., et al Impact of risperidone long-acting injectable on hospitalization and medication use in patients with schizophrenia. Value Health. 2005;8(6):A202-A203.
27. Bourin M, Jolliet P, Hery P., et al Is rehospitalization a measure of the efficacy of neuroleptics in the treatment of schizophrenia? Int J Psychiatry Clin Pract. 1998;2(4):275-278. (Pubitemid 29023491)
28. Svestka J, Náhunek K, Cesková E, et al. A 1-year experience with the administration of clopenthixol decanoate in schizophrenic psychoses [in Czech]. Cesk Psychiatr. 1984;80(3):146-154. (Pubitemid 14058008)
29. Waldmann KD, Neumann J. Clinical experience with depot neuroleptic treatment [in German]. Z Arztl Fortbild (Jena). 1984;78(20):853-856. (Pubitemid 15183292)
30. Michel G, Vásquez R, Basso L. Follow-up study of patients treated with depot phenothiazines in Valparaiso, Chile [in Spanish]. Bol Oficina Sanit Panam. 1981;91(5):418-427.
31. Tan CT, Ong TC, Chee KT The use of fluphenazine decanoate (Modecate) depot therapy in outpatient schizophrenics-a retrospective study. Singapore Med J. 1981;22(4):214-218. (Pubitemid 12105862)
32. Arató M, Erdós A. Experience with depot neuroleptics [in Hungarian]. Orv Hetil. 1979;120(17):1015-1021.
33. Devito RA, Brink L, Sloan C., et al Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions. J Clin Psychiatry. 1978;39(1):26-34.
34. Polonowita A, James NM Fluphenazine decanoate maintenance in schizophrenia: a retrospective study. N Z Med J. 1976;83(563):316-318.
35. Lindholm H. The consumption of inpatient psychiatric resources prior to and during treatment with a depot neuroleptic, perphenazine enanthate: a mirror study. Nord J Psychiatry. 1975;29(6):513-520.
36. Gottfries CG, Green L. Flupenthixol decanoate - in treatment of outpatients. Acta Psychiatr Scand suppl. 1974;50(s255):15-24.
37. Morritt C. Long-acting phenothiazines and schizophrenia. Nurs Mirror Midw iv es J. 1974;138(4):57-59.
38. Johnson DA, Freeman H. Long-acting tranquillizers. Practitioner. 1972;208(245):395-400.
39. Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand. 1971;47(4):420-430.
40. Malm U. Fluphenazine depot: the usefulness of neuroleptics in perspective [in Swedish]. Nord Psykiatr Tidsskr. 1971;25(4):309-314.
41. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196-201. (Pubitemid 28071427)
42. Kishimoto T, Agarwal V, Kishi T., et al Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1): 53-66.
43. Correll CU, Kishimoto T, Kane JM Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci. 2011;13(2):155-172.